PriceTargets.com logo

NervGen Pharma - NGEN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 356.85%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.94 As of 04/27/2026 12:21 PM ET
▲ +0.02 (0.51%)

This chart shows the closing price for NGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NervGen Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGEN

Analyst Price Target is $18.00
▲ +356.85% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NervGen Pharma in the last 3 months. The average price target is $18.00, with a high forecast of $18.00 and a low forecast of $18.00. The average price target represents a 356.85% upside from the last price of $3.94.

This chart shows the closing price for NGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in NervGen Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/27/2026HC WainwrightInitiated CoverageBuy$18.00
(Data available from 4/27/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

NervGen Pharma

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Read More

Today's Range

Now: $3.94
Low: $3.92
High: $4.13

50 Day Range

MA: N/A

52 Week Range

Now: $3.94
Low: $1.50
High: $6.30

Volume

116,900 shs

Average Volume

165,356 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NervGen Pharma?

The following Wall Street analysts have issued reports on NervGen Pharma in the last year: HC Wainwright.
View the latest analyst ratings for NGEN.

What is the current price target for NervGen Pharma?

0 Wall Street analysts have set twelve-month price targets for NervGen Pharma in the last year. Their average twelve-month price target is $18.00. HC Wainwright has the highest price target set, predicting NGEN will reach $18.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $18.00 for NervGen Pharma in the next year.
View the latest price targets for NGEN.

What is the current consensus analyst rating for NervGen Pharma?

NervGen Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NGEN will outperform the market and that investors should add to their positions of NervGen Pharma.
View the latest ratings for NGEN.

What other companies compete with NervGen Pharma?

Other companies that are similar to NervGen Pharma include Ainos, Alvotech, Aravive, Atlantic Coastal Acquisition Corp. II and Avidity Biosciences. Learn More about companies similar to NervGen Pharma.

How do I contact NervGen Pharma's investor relations team?

NervGen Pharma's physical mailing address is SUITE 1703 - 595 BURRARD STREET, VANCOUVER, British Columbia, Canada, V7X 1J1. The company's listed phone number is (604) 722-5361. The official website for NervGen Pharma is nervgen.com. Learn More about contacing NervGen Pharma investor relations.